RN1701
/ AlloRunning Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 05, 2026
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University
New P1 trial • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20
April 03, 2026
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
(clinicaltrials.gov)
- P1/2 | N=10 | Not yet recruiting | Sponsor: Affiliated Hospital of Nantong University
New P1/2 trial • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20
1 to 2
Of
2
Go to page
1